Efficacy and Safety of the DLL3/CD3 T-Cell Engager Obrixtamig in Patients With Extrapulmonary Neuroendocrine Carcinomas With High or Low DLL3 Expression: Results From an Ongoing Phase 1 Trial
Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.